Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Guangxi Medical University, Nanning 530021, China.
School of Basic Medical Sciences, Youjiang Medical University for Nationalities, Baise 533000, China.
Int J Mol Sci. 2023 Jun 7;24(12):9864. doi: 10.3390/ijms24129864.
To investigate the potential of H2-calponin (CNN2) as a serum biomarker for hepatocellular carcinoma (HCC), this study employed the serological analysis of recombinantly expressed cDNA clone (SEREX) technique to identify the presence of CNN2 antibody in the serum of patients with HCC and other tumors. The CNN2 protein was produced through genetic engineering and used as an antigen to determine the positive rate of serum CNN2 autoantibodies via indirect enzyme-linked immunosorbent assay (ELISA). In addition, the mRNA and protein expressions of CNN2 in cells and tissues were evaluated using RT-PCR, in situ RT-PCR, and immunohistochemistry methods. The HCC group exhibited a significantly higher positive rate of anti-CNN2 antibody (54.8%) compared to gastric cancer (6.5%), lung cancer (3.2%), rectal cancer (9.7%), hepatitis (3.2%), liver cirrhosis (3.2%), and normal tissues (3.1%). The positive rates of CNN2 mRNA in HCC with metastasis, non-metastatic HCC, lung cancer, gastric cancer, nasopharyngeal cancer, liver cirrhosis, and hepatitis were 56.67%, 41.67%, 17.5%, 10.0%, 20.0%, 53.13%, and 41.67%, respectively. Meanwhile, the positive rates of CNN2 protein were 63.33%, 37.5%, 17.5%, 27.5%, 45%, 31.25%, and 20.83%, respectively. The down-regulation of CNN2 could inhibit the migration and invasion of liver cancer cells. CNN2 is a newly identified HCC-associated antigen that is implicated in the migration and invasion of liver cancer cells, making it a promising target for liver cancer therapy.
为了研究 H2-钙调蛋白（CNN2）作为肝细胞癌（HCC）血清生物标志物的潜力，本研究采用重组 cDNA 克隆的血清学分析（SEREX）技术，以确定 HCC 患者和其他肿瘤患者血清中是否存在 CNN2 抗体。CNN2 蛋白通过基因工程生产，并用作抗原，通过间接酶联免疫吸附试验（ELISA）来确定血清 CNN2 自身抗体的阳性率。此外，使用 RT-PCR、原位 RT-PCR 和免疫组织化学方法评估 CNN2 在细胞和组织中的 mRNA 和蛋白表达。HCC 组抗 CNN2 抗体的阳性率（54.8%）明显高于胃癌（6.5%）、肺癌（3.2%）、直肠癌（9.7%）、肝炎（3.2%）、肝硬化（3.2%）和正常组织（3.1%）。转移 HCC、非转移性 HCC、肺癌、胃癌、鼻咽癌、肝硬化和肝炎中 CNN2 mRNA 的阳性率分别为 56.67%、41.67%、17.5%、10.0%、20.0%、53.13%和 41.67%。同时，CNN2 蛋白的阳性率分别为 63.33%、37.5%、17.5%、27.5%、45%、31.25%和 20.83%。CNN2 的下调可抑制肝癌细胞的迁移和侵袭。CNN2 是一种新鉴定的 HCC 相关抗原，参与肝癌细胞的迁移和侵袭，是肝癌治疗的有前途的靶点。
